Medical College Of Wisconsin
Cancer surgeon runs the globe to raise testicular cancer awareness
Clark Gamblin, MD, MS, MBA, ran “on the moon” in Antarctica, under hang gliders in South Africa, and next to a starlit ocean in Australia.
Consolidative HSCT may not be necessary for some patients with mantle cell lymphoma
SAN DIEGO — Autologous hematopoietic stem cell transplantation did not benefit adults with mantle cell lymphoma in first complete remission after induction, according to randomized phase 3 data presented at ASH Annual Meeting and Exposition.
Tandem non-cryopreserved CAR-T exhibits ‘favorable’ activity in advanced DLBCL
SAN DIEGO — A rapidly delivered tandem chimeric antigen receptor T-cell therapy produced favorable outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma, according to interim results of a phase 2 trial.
Efanesoctocog alfa offers ‘highly efficacious protection’ to children with hemophilia A
Efanesoctocog alfa prophylaxis exhibited high sustained factor VIII activity among younger children with severe hemophilia, according to findings published in The New England Journal of Medicine.
Diabetes prevalence higher among people living in historically redlined areas
Neighborhoods that were historically redlined on Home Owners’ Loan Corporation maps in the 1930s are associated with higher diabetes prevalence than non-redlined areas after adjusting for 2010 population figures, according to study data.
ASH elects three to leadership positions
Three physicians have been elected to serve in leadership roles on ASH’s executive committee.
Hemiarthroplasty for femoral fracture associated with lower risk of dislocation vs. THA
Published results showed hemiarthroplasty was associated with a lower risk of hip dislocation at 1 year compared with total hip arthroplasty, although researchers questioned whether the results are clinically significant.
ASCO studies reveal ‘unprecedented’ benefit with CAR-T as earlier treatment
Now that chimeric antigen receptor T-cell therapy has become part of the treatment landscape in hematologic malignancies, researchers are focused on developing more potent, less toxic agents that can be used in earlier treatment settings.
Cilta-cel CAR-T provides ‘unprecedented’ benefit for advanced multiple myeloma
CHICAGO — Ciltacabtagene autoleucel significantly extended PFS compared with standard therapy for adults with relapsed and lenalidomide-refractory multiple myeloma, results from the randomized phase 3 CARTITUDE-4 study showed.
Split-dose R-CHOP regimen effective for older adults with newly diagnosed lymphoma
CHICAGO — A split-dose approach to the standard R-CHOP chemotherapy regimen resulted in a 71% complete response rate among older adults with newly diagnosed diffuse large B-cell lymphoma, results from a phase 2 study showed.